Genetic biomarkers of various ischemic stroke subtypes
- Authors: Minibaeva G.M.1, Novikova L.B1, Viktorova T.V1
-
Affiliations:
- Bashkir State Medical University
- Issue: Vol 27, No 3 (2020)
- Pages: 96-99
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/312608
- DOI: https://doi.org/10.18565/pharmateca.2020.3.96-99
- ID: 312608
Cite item
Open Access
Access granted
Abstract
Background. Ischemic stroke (IS) is one of the leading causes of death and disability worldwide. There are atherothrombotic (ATS) and cardioembolic (CES) subtypes of IS. For timely diagnosis and prediction of outcomes for different IS subtypes, an important task is to identify the most informative biomarkers, including genetic ones. Objective. Search for genetic biomarkers to predict the outcome of various IS subtypes based on an analysis of the CD46 gene expression level. Methods. The study used RNA samples of 79 unrelated individuals, including 21 patients with CES, 20 with ATS, 21 with transient ischemic attack, and 17 healthy individuals. In order to study the role of the CD46 gene in the development of IS, we performed a molecular genetic analysis of its expression level. Results. The important role of the CD46 gene in the development of ATS has been shown. A comparative analysis with the control group showed that ATS men showed a significant increase in the CD46 gene expression level, while in women, on the contrary, the the CD46 gene expression level was significantly lower. Conclusion. The data obtained indicate the important role of the CD46 gene in the development of this pathology and the possibility of its use as a genetic biomarker of the atherothrombotic IS.
Full Text
About the authors
Guzel M. Minibaeva
Bashkir State Medical University
Email: Guzel-hisamieva@rambler.ru
Postgraduate Student at the Department of Neurology IPGE Ufa, Russia
L. B Novikova
Bashkir State Medical UniversityUfa, Russia
T. V Viktorova
Bashkir State Medical UniversityUfa, Russia
References
- Суслина З.А., Варакин Ю.Я., Верещагин Н.В. Сосудистые заболевания головного мозга. М.: МЕДпресс-информ, 2009. 352 с. [
- Гусев Е.И., Скворцова В.И., Стаховская Л.В. Проблемы инсульта в Российской Федерации: время активных действий. Журнал неврологии и психиатрии им. С.С. Корсакова. 2007;8:410
- Гусев Е.И., Мартынов М.Ю., Камчатнов П.Ридр. Церебральный инсульт Consilium Medicum. 2014;12:13-7
- Гераскина Л.А. Кардиоэмболический инсульт: многообразие причин и современные подходы к профилактике. Неврология, нейропсихиатрия, психосоматика. 2013;5(4):60-5
- Машин В.В., Котова Е.Ю., Пинкова Е.А. Заболеваемость и факторы риска инсульта. Возможности профилактики. Неврологический вестник им. В.М. Бехтерева. 2007;XXXIX(вып. 1 [прил.]):156-57
- Инсульт: диагностика, лечение, профилактика Под ред З.А. Суслиной, М.А. Пирадова. М.: МЕДпресс-информ, 2008. 288 с
- Jickling G.C., Xu H., Stamova B., et al. Signatures of cardioembolic and large-vessel ischemic stroke. Ann Neurol. 2010;68(5):681-92. Doi: 10.1002/ ana.22187.
- Jickling G.C., Stamova B., Ander B.P, et al. Prediction of cardioembolic, arterial, and lacunar causes of cryptogenic stroke by gene expression and infarct location. Stroke. 2012;43(8): 2036-
- Wang Z.Y., Sun Z.R., Zhang L.M. The relationship between serum mannose-binding lectin levels and acute ischemic stroke risk. Neurochem Res. 2014;39(2):248-53. doi: 10.1007/s11064- 013-1214-x.
- Hansson G.K., Robertson A.K., Soderberg-Naucler C. Inflammation and atherosclerosis. Annu Rev Pathol. 2006; 1: 297-329. 10.1146/annurev. pathol.1.110304.100100
- Seifert P.S., Hansson G.K. Complement receptors and regulatory proteins in human atherosclerotic lesions. Arteriosclerosis. 1989; 9(6): 802-11.
- Song F.Y., Wu M.H., Zhu L.H., et al. Elevated Serum Mannose-Binding Lectin Levels Are Associated with Poor Outcome After Acute Ischemic Stroke in Patients with Type 2 Diabetes. Mol Neurobiol. 2015;52(3):1330-40. doi: 10.1007/s12035- 014-8941-0.
- Szplaki G., Szegedi R., Hirschberg K., et al. Strong complement activation after acute ischemic stroke is associated with unfavorable outcomes. Atherosclerosis. 2009;204(1):315-20. doi: 10.1016/j.atherosclerosis.2008.07.044.
Supplementary files
